Genelux Corporation GNLX
2.28 USD +0.04 (+1.79%)
Regular-session close
2.41 +0.13 +5.70%
After hours · Nov 19, 4:00 PM ET
2.11 Day range 2.32
1.77 52-week range 5.89
- YTD
- -47.71%
- 1 year
- -54.40%
News
benzinga.com Genelux Q3 EPS $(0.23) Misses $(0.19) Estimate Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.19) by 21.05 percent. This is a 9.52 percent decrease over losses of $(0.21)…
globenewswire.com Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Recently published Phase 1b/2 OLVI-VEC-202-SCLC case report extends evidence for…
defenseworld.net Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX) Genelux (NASDAQ: GNLX - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
globenewswire.com Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy -- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy…
globenewswire.com Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional…
defenseworld.net Genelux (GNLX) Projected to Post Quarterly Earnings on Thursday Genelux (NASDAQ: GNLX - Get Free Report) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.20) per share…
globenewswire.com Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer - Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -
globenewswire.com Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates -- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates…
globenewswire.com Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in…
globenewswire.com Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and…
globenewswire.com Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an…
globenewswire.com Genelux Corporation Announces Proposed Public Offering of Common Stock WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a…
globenewswire.com Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.,…
globenewswire.com Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --
globenewswire.com Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter…
globenewswire.com Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General…
zacks.com Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know Genelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
globenewswire.com Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter…
globenewswire.com Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer –
zacks.com Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising…
globenewswire.com Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an…
